World's Best Scientists 2026 revealed!
Margaret A. Shipp

Margaret A. Shipp

D-Index & Metrics

Medicine

D-Index
103
Citations
60043
World Ranking
7185
National Ranking
3769

Margaret A. Shipp publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Margaret A. Shipp sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 318 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Margaret A. Shipp D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Margaret A. Shipp sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2014 - Member of the National Academy of Medicine (NAM)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Margaret A. Shipp is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine, with significant contributions within Oncology, Pathology and Forensic Medicine, Molecular Biology, Immunology, and Neurology.

The main topics of their work include:

  • Lymphoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Cancer Genomics and Diagnostics

Margaret A. Shipp has contributed to a number of recent papers, highlighting developments in lymphoma and immunotherapy. Selected recent publications include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma (2020, Nature Medicine)
  • Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma (2024, New England Journal of Medicine)
  • Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma (2023, Blood)
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study (2023, Blood Advances)

The most frequent co-authors collaborating with Margaret A. Shipp include:

  • Scott J. Rodig (23 joint publications)
  • Philippe Armand (19 joint publications)
  • Robert Redd (13 joint publications)
  • Vignesh Shanmugam (13 joint publications)
  • Pier Luigi Zinzani (11 joint publications)

Publications by Margaret A. Shipp appear repeatedly in key scientific journals such as:

  • Blood (19 publications)
  • Hematological Oncology (6 publications)
  • Blood Advances (5 publications)
  • ONCOLOGY (5 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (5 publications)

The scientist has been recognized with memberships in professional organizations, including being named a Member of the National Academy of Medicine in 2014 and a Member of the Association of American Physicians.

Best Publications

  • A predictive model for aggressive non-Hodgkin's lymphoma

    M. A. Shipp;D. P. Harrington;J. R. Anderson;J. O. Armitage

  • Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    B D Cheson;S J Horning;B Coiffier;M A Shipp

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

    Margaret A. Shipp;Ken N. Ross;Pablo Tamayo;Andrew P. Weng

  • Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    Bjoern Chapuy;Chip Stewart;Andrew J Dunford;Jaegil Kim

  • Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

    Michael R. Green;Stefano Monti;Scott J. Rodig;Przemyslaw Juszczynski

  • Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    Jens G. Lohr;Petar Stojanov;Petar Stojanov;Michael S. Lawrence;Daniel Auclair

  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

    Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

    Jonathan W. Friedberg;Jeff Sharman;John Sweetenham;Patrick B. Johnston

  • PD-L1 EXPRESSION IS CHARACTERISTIC OF A SUBSET OF AGGRESSIVE B-CELL LYMPHOMAS AND VIRUS-ASSOCIATED MALIGNANCIES

    Benjamin J. Chen;Bjoern Chapuy;Jing Ouyang;Heather H. Sun

  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Bjoern Chapuy;Michael R. McKeown;Charles Y. Lin;Stefano Monti

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Margaretha G.M. Roemer;Ranjana H. Advani;Azra H. Ligon;Yasodha Natkunam

  • Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma

    A Rohatiner;F d'Amore;B Coiffier;D Crowther

  • Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

    Michael R Green;Scott J. Rodig;Przemyslaw Juszczynski;Jing Ouyang

  • Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Philippe Armand;Margaret A. Shipp;Vincent Ribrag;Jean Marie Michot

Frequent Co-Authors

Scott J. Rodig
Scott J. Rodig Harvard University
Philippe Armand
Philippe Armand Harvard University
Donna Neuberg
Donna Neuberg Harvard University
Jeffery L. Kutok
Jeffery L. Kutok Epizyme (United States)
Todd R. Golub
Todd R. Golub Harvard University
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Gad Getz
Gad Getz Broad Institute
Geraldine S. Pinkus
Geraldine S. Pinkus Brigham and Women's Hospital
Kerry J. Savage
Kerry J. Savage University of British Columbia
Jon C. Aster
Jon C. Aster Harvard Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but prefer flexibility, several online options can help you advance quickly and affordably. For registered nurses looking to earn a bachelor’s degree without breaking the bank, the cheapest rn to bsn program options offer a pathway to increased job opportunities and higher salaries.

Those without a nursing background who want to enter the field at the master’s level can explore direct entry msn programs online. These programs allow non-nurses to fast-track their education and quickly gain essential qualifications.

If admission barriers concern you, finding the easiest bsn program to get into can simplify your journey—letting you start your nursing career sooner.

For those interested in supporting the healthcare system without direct patient care, consider an online medical billing and coding with financial aid program. These flexible courses are ideal for launching a medical office career, often with financial support available.

Best Scientists Citing Margaret A. Shipp

Trending Scientists

Recently Published Articles